Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernd Hohenstein

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
International Journal of Oncology|September 25, 2008
The dual EGF/VEGF receptor tyrosine kinase inhibitor AEE788 inhibits growth of human hepatocellular carcinoma xenografts in nude miceKinya Okamoto, Daniel Neureiter, Beate Alinger, et al.
Journal of Clinical Lipidology|May 22, 2016
Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trialPatrick M Moriarty, Klaus G Parhofer, Stephan P Babirak, et al.
Journal of the American Society of Nephrology : JASN|August 5, 2017
Interference with Gs<i>α</i>-Coupled Receptor Signaling in Renin-Producing Cells Leads to Renal Endothelial DamagePeter Lachmann, Linda Hickmann, Anne Steglich, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|September 16, 2022
Post COVID and Apheresis - Where are we Standing?Charlotte Steenblock, Romy Walther, Sergey Tselmin, et al.
European Heart Journal|August 31, 2016
Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trialPatrick M Moriarty, Klaus G Parhofer, Stephan P Babirak, et al.
Infection|April 29, 2022
SARS-CoV-2 infection in chronic kidney disease patients with pre-existing dialysis: description across different pandemic intervals and effect on disease course (mortality)Lisa Pilgram, Lukas Eberwein, Bjoern-Erik O Jensen, et al.
Journal of the American Society of Nephrology : JASN|June 9, 2012
Histones from dying renal cells aggravate kidney injury via TLR2 and TLR4Ramanjaneyulu Allam, Christina Rebecca Scherbaum, Murthy Narayana Darisipudi, et al.
Scientific Reports|June 7, 2022
Overexpression of alanine-glyoxylate aminotransferase 2 protects from asymmetric dimethylarginine-induced endothelial dysfunction and aortic remodelingRoman N Rodionov, Natalia Jarzebska, Dmitrii Burdin, et al.
European Heart Journal|May 19, 2026
Lipoprotein apheresis in the era of new lipid-lowering therapiesFrancesco Sbrana, Beatrice Dal Pino, Volker J J Schettler, et al.
Kidney International Reports|December 19, 2024
SGLT2-Inhibition in Patients With Alport SyndromeJan Boeckhaus, Daniel P Gale, James Simon, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
International Journal of Oncology|September 25, 2008
The dual EGF/VEGF receptor tyrosine kinase inhibitor AEE788 inhibits growth of human hepatocellular carcinoma xenografts in nude miceKinya Okamoto, Daniel Neureiter, Beate Alinger, et al.
Journal of Clinical Lipidology|May 22, 2016
Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trialPatrick M Moriarty, Klaus G Parhofer, Stephan P Babirak, et al.
Journal of the American Society of Nephrology : JASN|August 5, 2017
Interference with Gs<i>α</i>-Coupled Receptor Signaling in Renin-Producing Cells Leads to Renal Endothelial DamagePeter Lachmann, Linda Hickmann, Anne Steglich, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|September 16, 2022
Post COVID and Apheresis - Where are we Standing?Charlotte Steenblock, Romy Walther, Sergey Tselmin, et al.
European Heart Journal|August 31, 2016
Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trialPatrick M Moriarty, Klaus G Parhofer, Stephan P Babirak, et al.
Infection|April 29, 2022
SARS-CoV-2 infection in chronic kidney disease patients with pre-existing dialysis: description across different pandemic intervals and effect on disease course (mortality)Lisa Pilgram, Lukas Eberwein, Bjoern-Erik O Jensen, et al.
Journal of the American Society of Nephrology : JASN|June 9, 2012
Histones from dying renal cells aggravate kidney injury via TLR2 and TLR4Ramanjaneyulu Allam, Christina Rebecca Scherbaum, Murthy Narayana Darisipudi, et al.
Scientific Reports|June 7, 2022
Overexpression of alanine-glyoxylate aminotransferase 2 protects from asymmetric dimethylarginine-induced endothelial dysfunction and aortic remodelingRoman N Rodionov, Natalia Jarzebska, Dmitrii Burdin, et al.
European Heart Journal|May 19, 2026
Lipoprotein apheresis in the era of new lipid-lowering therapiesFrancesco Sbrana, Beatrice Dal Pino, Volker J J Schettler, et al.
Kidney International Reports|December 19, 2024
SGLT2-Inhibition in Patients With Alport SyndromeJan Boeckhaus, Daniel P Gale, James Simon, et al.
Pageof 7